المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators

المساهمون: Gennigens, Christine

المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406

الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test

المؤلفون: Motzer R., Alekseev B., Rha S. -Y., Porta C., Eto M., Powles T., Grunwald V., Hutson T. E., Kopyltsov E., Mendez-Vidal M. J., Kozlov V., Alyasova A., Hong S. -H., Kapoor A., Gordoa T. A., Merchan J. R., Winquist E., Maroto P., Goh J. C., Kim M., Gurney H., Patel V., Peer A., Procopio G., Takagi T., Melichar B., Rolland F., de Giorgi U., Wong S., Bedke J., Schmidinger M., Dutcus C. E., Smith A. D., Dutta L., Mody K., Perini R. F., Xing D., Choueiri T. K., Boccardo F.

المساهمون: Motzer, R., Alekseev, B., Rha, S. -Y., Porta, C., Eto, M., Powles, T., Grunwald, V., Hutson, T. E., Kopyltsov, E., Mendez-Vidal, M. J., Kozlov, V., Alyasova, A., Hong, S. -H., Kapoor, A., Gordoa, T. A., Merchan, J. R., Winquist, E., Maroto, P., Goh, J. C., Kim, M., Gurney, H., Patel, V., Peer, A., Procopio, G., Takagi, T., Melichar, B., Rolland, F., de Giorgi, U., Wong, S., Bedke, J., Schmidinger, M., Dutcus, C. E., Smith, A. D., Dutta, L., Mody, K., Perini, R. F., Xing, D., Choueiri, T. K., Boccardo, F.

مصطلحات موضوعية: Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agent, Antineoplastic Combined Chemotherapy Protocol, Carcinoma, Renal Cell, Everolimu, Female, Human, Kidney Neoplasm, Male, Middle Aged, Phenylurea Compound, Programmed Cell Death 1 Receptor, Progression-Free Survival, Protein Kinase Inhibitor, Quinoline, Sunitinib, Survival Analysis

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33616314; info:eu-repo/semantics/altIdentifier/wos/WOS:000637799800007; volume:384; firstpage:1289; lastpage:1300; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11567/1046356Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85103105017

الإتاحة: https://doi.org/10.1056/NEJMoa2035716Test
http://hdl.handle.net/11567/1046356Test

المؤلفون: Miriam Koopman, Cees J van Groeningen, Ninja Antonini, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Otilia Dalesio, Dirk J. Richel, A. Vos, C.J. Rodenburg, Annemieke Cats, Harm Sinnige, Geert Jan Creemers, Cornelis J. A. Punt, Jolien Tol, Emile E. Voest, Frans L. G. Erdkamp, Linda Mol, Jolanda G Schrama, Johan H. J. M. van Krieken

المساهمون: CCA -Cancer Center Amsterdam, Oncology, Other departments, Medical oncology, CCA - Innovative therapy, Faculteit der Geneeskunde

المصدر: New England journal of medicine, 360(6), 563-572. Massachussetts Medical Society
The New England Journal of Medicine, 360, 563-72
de Nooy-van Tol, J, Koopman, M, Cats, A, Rodenburg, C J, Creemers, G J M, Schrama, J G, Erdkamp, F L G, Vos, A H, van Groeningen, C J, Sinnige, H A M, Richel, D J, Voest, E E, Dijkstra, J R, Vink-Borger, M E, Antonini, N F, Mol, L, van Krieken, J H J M, Dalesio, O & Punt, C J A 2009, ' Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer ', New England Journal of Medicine, vol. 360, no. 6, pp. 563-572 . https://doi.org/10.1056/NEJMoa0808268Test
The New England Journal of Medicine, 360, 6, pp. 563-72
New England Journal of Medicine, 360(6), 563-572. Massachussetts Medical Society
The New England journal of medicine, 360(6), 563-572. Massachussetts Medical Society

مصطلحات موضوعية: Oncology, Male, Vascular Endothelial Growth Factor A, Genetics and epigenetic pathways of disease [NCMLS 6], Organoplatinum Compounds, Colorectal cancer, Cetuximab, Kaplan-Meier Estimate, medicine.disease_cause, Deoxycytidine, Immune Regulation [NCMLS 2], Antineoplastic Combined Chemotherapy Protocols, Treatment Failure, Neoplasm Metastasis, Aged, 80 and over, Antibodies, Monoclonal, General Medicine, Middle Aged, Bevacizumab, ErbB Receptors, Oxaliplatin, Female, KRAS, Fluorouracil, Colorectal Neoplasms, medicine.drug, Adult, medicine.medical_specialty, Age-related aspects of cancer [ONCOL 2], Antibodies, Monoclonal, Humanized, Disease-Free Survival, Capecitabine, Proto-Oncogene Proteins p21(ras), Translational research [ONCOL 3], Internal medicine, Proto-Oncogene Proteins, medicine, Humans, neoplasms, Aged, Hereditary cancer and cancer-related syndromes [ONCOL 1], business.industry, Cancer, medicine.disease, digestive system diseases, Surgery, Regimen, Mutation, Quality of Life, ras Proteins, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d4f0da267a28af2516fc8e5e361490Test
https://doi.org/10.1056/NEJMoa0808268Test